Apellis Pharmaceuticals, Inc. (APLS) Social Stream

Featured Post From StockTwits About APLS

$APLS "Potentially Transformative" results from DARBY & OAKS expected in SEP. This is a pair of P3 trails of Pegcetacoplan in Geographic Atrophy (GA). The PE is change in lesion size at 12 months vs placebo. This PE was met in the P2 "FILLY" trial with a p-value of 0.008. Moreover, the treatment benefit continued to improve out to 18 months (End of Treatment), and then declined on discontinuation. GA is an advanced form of age-related macular degeneration (AMD), a leading cause of blindness. There are no approved treatments for GA, which afflicts 1M patients in the US and 5M globally.